Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ide-Cel for Multiple Myeloma Patients Post Hematopoietic Cell Transplantation
NCT05393804Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2022
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of idecabtagene vicleucel in multiple myeloma (MM) (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Feasibility of manufacturing Ide-Cel at 1 year. Started May 2022; status: active, not recruiting.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05393804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393804.